Session Information
2009 Midyear Clinical Meeting
Click here to go to the previous page
Contemporary Considerations in the Evaluation of Antithrombotic Use in Percutaneous Coronary Intervention
Track: Educational Sessions (CE)
Program Code: 253-L01
Date: Wednesday, December 9, 2009
Time: 8:00 AM to 9:30 AM EST
Location: 2405 - Veronese
MEETING PLANNING ASSOCIATE:   Click the plus sign to see more detailed information about each speaker.
 Alisa Goetz, PharmD, Director, Clinical Data and Analytics, Cardinal Health
PRESENTER(S):   Click the plus sign to see more detailed information about each speaker.
 Alisa Goetz, PharmD, Director, Clinical Data and Analytics, Cardinal Health
 Carl Peterson, PharmD, Clinical Director, Cardiovascular Diseases, Cardinal Health
Description
ACPE Activity #204-000-09-253-L01P
1.5 Contact Hours / Knowledge-based
Educational Content: Level 2
Moderator: Alisa E. Goetz, PharmD, Director, Clinical Data and Analytics, Cardinal Health, Houston, TX

8:00 a.m. – 8:05 a.m.
Announcements

8:05 a.m. – 8:15 a.m.
Review of Current Guidelines for Antithrombotic Use in PCI
Carl Peterson, PharmD, Clinical Director, Cardiovascular Diseases, Cardinal Health, Houston, TX

8:15 a.m. – 8:35 a.m.
Review of Recent PCI Clinical Trial Results
Carl Peterson

8:35 a.m. – 8:40 a.m.
Case Study Presentation
Carl Peterson

8:40 a.m. – 9:00 a.m.
Evaluation of Real World PCI Data
Alisa E. Goetz

9:00 a.m. – 9:05 a.m.
Audience Polling: Practice Patterns of Participants and Case Study Evaluation
Alisa E. Goetz

9:05 a.m. – 9:20 a.m.
Impact Analysis Comparing Real World Data to Clinical Trial Data Including Economic Implications
Carl Peterson

9:20 a.m. – 9:30 a.m.
Conclusions, Questions, Answers, and Discussion

Learning Objectives:

LEARNER OUTCOMES:
  • Describe and interpret the results of recent clinical trial data including the REPLACE, ISAR-REACT, and ACUITY trials.
  • Describe PCI drug utilization data for over 50 acute care hospitals with focus on the use of bivalrudin and glycoprotein IIb/IIIa receptor inhibiters (GPI).
  • Identify variances between clinical practices, guideline recommendations, and results from recent clinical trials.
  • Summarize current clinical guidelines for the use of antithrombotics in percutaneous coronary intervention (PCI).
  • Summarize the clinical and economic implications of variance in antithrombotic drug use during PCI in clinical practice, guideline recommendations, and recent clinical trial results.


Audio Synchronized to PowerPoint
(Code: 253-L01)
Attendee:Free
  
This session is a part of:
Handout Online
View